331 related articles for article (PubMed ID: 29480432)
1. Frontline Therapy of CLL: Evolving Treatment Paradigm.
Boddy CS; Ma S
Curr Hematol Malig Rep; 2018 Apr; 13(2):69-77. PubMed ID: 29480432
[TBL] [Abstract][Full Text] [Related]
2. Optimal management of the young patient CLL patient.
Allan JN; Furman RR
Best Pract Res Clin Haematol; 2018 Mar; 31(1):73-82. PubMed ID: 29452669
[TBL] [Abstract][Full Text] [Related]
3. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies.
Kojima K; Burger JA
J Clin Exp Hematop; 2020 Dec; 60(4):130-137. PubMed ID: 32404571
[TBL] [Abstract][Full Text] [Related]
4. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
[TBL] [Abstract][Full Text] [Related]
6. Selecting Frontline Therapy for CLL in 2018.
Jain N
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):242-247. PubMed ID: 30504317
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies.
Rafei H; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):1-12. PubMed ID: 28549767
[TBL] [Abstract][Full Text] [Related]
8. Novel agents versus chemotherapy as frontline treatment of CLL.
Piggin A; Bayly E; Tam CS
Leuk Lymphoma; 2017 Jun; 58(6):1320-1324. PubMed ID: 28271950
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
10. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Suzumiya J; Takizawa J
Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666
[TBL] [Abstract][Full Text] [Related]
11. Novel agents in chronic lymphocytic leukemia.
Lamanna N; O'Brien S
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):137-145. PubMed ID: 27913472
[TBL] [Abstract][Full Text] [Related]
12. How should we sequence and combine novel therapies in CLL?
Davids MS
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):346-353. PubMed ID: 29222277
[TBL] [Abstract][Full Text] [Related]
13. Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Huang SJ; Gerrie AS; Young S; Tucker T; Bruyere H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn L; Toze CL
Leuk Res; 2020 Apr; 91():106335. PubMed ID: 32114372
[TBL] [Abstract][Full Text] [Related]
14. NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation.
Mikudina B; Goodall M; Adler AI
Lancet Oncol; 2017 Mar; 18(3):289-290. PubMed ID: 28130034
[No Abstract] [Full Text] [Related]
15. Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia.
Khan Y; Lyou Y; El-Masry M; O'Brien S
Expert Rev Hematol; 2020 Jan; 13(1):31-38. PubMed ID: 31756301
[No Abstract] [Full Text] [Related]
16. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
17. What is the best frontline therapy for patients with CLL and 17p deletion?
Badoux XC; Keating MJ; Wierda WG
Curr Hematol Malig Rep; 2011 Mar; 6(1):36-46. PubMed ID: 21153774
[TBL] [Abstract][Full Text] [Related]
18. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
[TBL] [Abstract][Full Text] [Related]
19. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown JR; Hallek MJ; Pagel JM
Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
[TBL] [Abstract][Full Text] [Related]
20. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
Lee HJ; Gallardo M; Ma H; Zhang X; Larsson CA; Mejia A; Hornbaker MJ; Qi Y; Su X; Pageon LR; Quintas-Cardama A; Post SM
Blood Cancer J; 2016 Jun; 6(6):e434. PubMed ID: 27284738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]